{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-006321","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.188838+00:00","generated_at":"2026-06-05T18:59:37.254097+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ardelyx reports FY2023 revenue $124.5M; IBSRELA sales $80.1M, guides 2024 $140-150M","bullets":["IBSRELA net product sales $80.1M in FY2023, Q4 $28.1M (+26% QoQ); guides 2024 sales $140-150M.","XPHOZAH launch nets $2.5M in Q4 2023; initiated real-world study.","Total revenue $124.5M in 2023 (up 138% YoY from $52.2M); net loss $66.1M ($0.30 per share).","Cash and investments $184.3M at year-end, up from $123.9M; drew $22.4M from SLR term loan.","Kyowa Kirin launched PHOZEVEL (tenapanor) in Japan Feb 20, 2024; Ardelyx received $3M milestone from Fosun."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-006321","json":"https://secwatch.observer/filing/0001628280-24-006321.json","markdown":"https://secwatch.observer/filing/0001628280-24-006321.md","text":"https://secwatch.observer/filing/0001628280-24-006321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024006321/0001628280-24-006321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024006321/ardx-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T18:59:37.254097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ad62e3e2a8d3fb665b9870a747ff42aa1825122","claim":"ARDELYX, INC. updated its the fourth quarter of 2023 guidance (initiated).","evidence_excerpt":"During the fourth quarter of 2023, U.S. net product sales revenue was $28.1 million, reflecting 26% growth compared to the third quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024006321/0001628280-24-006321-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7cbf4b17b3184f8bf378c790662c03675e18ac86","claim":"ARDELYX, INC. reported the year ended December 31, 2023 results: revenue Total revenues for the year ended December 31, 2023 were $124.5 million. Guidance initiated.","evidence_excerpt":"Total revenues for the year ended December 31, 2023 were $124.5 million, compared to $52.2 million in total revenues in 2022, reflecting increased net product sales, licensing revenues and product supply revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024006321/0001628280-24-006321-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"Total revenues for the year ended December 31, 2023 were $124.5 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}